SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

Apricus Biosciences, Inc. (APRI)

APRI RSS Feed
Add APRI Price Alert      Hide Sticky   Hide Intro
Moderator: carlodb1978, mecosmo2, Chillin up north
Search This Board: 
Last Post: 2/19/2017 8:49:12 AM - Followers: 193 - Board type: Free - Posts Today: 2

Apricus Biosciences, Inc. (APRI) 

 

 

http://www.apricusbio.com/

 

 

 

 

Company Address:

11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041

 CIK:   0001017491

Apricus Website:    http://www.apricusbio.com/index.html

 

 
 

NexACT® - Multi-Route Drug Delivery Technology

NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.

This technology is useful for:
  • Penetrating, proprietary, topical & transdermal formulations.
    Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
    Delivering siRNA therapeutics into the cells; in vivo validated
    Development of more effective, penetrating cosmeceutic formulations
    Preservative

The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013.  Vitaros has been launched in all European Union countries by partner pharmaceutical companies.  Additional agreements for marketing Vitaros have been established.  For more information see the company's most recent 10K SEC filing.

In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S.  The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016.  For more information see the company's most recent 10K SEC filing.


The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.

In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism.  In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.
.

 Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001017491&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Share Structure:
Outstanding Shares
 61,78M

Authorized Shares
75,000,000
  

Investor Relations:
ir@apricusbio.com
Tel: +1-858 222-8041

Matthew Beck
The Trout Group
:(646)378 2933

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 


                                                                           
Image result for vitaros                                                  

Image result for vitaros

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
APRI
Current Price
Volume:
Bid Ask Day's Range
SureTrader
APRI News: Amended Statement of Ownership (sc 13g/a) 02/14/2017 05:58:24 PM
APRI News: Amended Statement of Ownership (sc 13g/a) 02/10/2017 04:10:52 PM
APRI News: Current Report Filing (8-k) 02/09/2017 06:06:47 AM
APRI News: Apricus Biosciences Receives Positive Nasdaq Listing Determination 02/09/2017 06:00:27 AM
APRI News: Apricus Biosciences Receives Positive Nasdaq Listing Determination 02/09/2017 06:00:00 AM
PostSubject
#26903   Nasdaq.com earnings projections. .Dec 2016 0.01 0.01 0.01 1 0 0 mecosmo2 02/19/17 08:49:12 AM
#26902   Who says they do?? You. casinokid11211 02/19/17 06:21:16 AM
#26901   APRI has projected earnings of .26 by end mecosmo2 02/18/17 12:34:27 PM
#26893   It's going "higher and higher straight up we'll Noodle2 02/17/17 02:16:47 PM
#26892   how high is this going to go? slyguy8888 02/17/17 01:04:57 PM
#26891   Nice grow !!!! Aprilov 02/17/17 12:53:34 PM
#26890   Thanks Grow. PuuliTuku 02/17/17 12:28:59 PM
#26889   Yes, the cash machine is ringing according to mecosmo2 02/17/17 12:18:08 PM
#26888   What is this all about, is there a Clariske 02/17/17 12:17:45 PM
#26887   Nice run up for you guys. Hope growtheport 02/17/17 11:45:22 AM
#26886   good points carlo eicoman 02/17/17 10:40:28 AM
#26885   Probably the company is making cash with the carlodb1978 02/16/17 08:29:04 PM
#26884   Break out will drive the stock to 5.25, eliminatore2204 02/16/17 06:12:05 PM
#26883   Nice up today.. could run back in the leonardo1 02/16/17 01:24:49 PM
#26882   Something is going on. Indices are down but Noodle2 02/16/17 12:18:16 PM
#26881   Carl or KKR would make this a $25-30 stock. Noodle2 02/16/17 12:16:20 PM
#26880   Let s see if denner will bring icahn carlodb1978 02/16/17 12:14:11 PM
#26879   It's going bonkers!!! Noodle2 02/16/17 09:53:34 AM
#26878   APRI should have a stellar Q4, so the Noodle2 02/15/17 03:41:11 PM
#26877   Is APRI doing a PhIII trial? Noodle2 02/15/17 03:38:07 PM
#26876   Jeez that wont work!,. .Its full of badd Bacteria!! mecosmo2 02/15/17 01:25:26 PM
#26875   Ha ha ha ha Aprilov 02/15/17 12:16:34 PM
#26874   Casino how much have u been paid for carlodb1978 02/15/17 11:05:39 AM
#26873   Apricus value is 250 mlns with fda approval. carlodb1978 02/15/17 09:01:52 AM
#26872   The 3 top holders are. .SARISSA CAPITAL MANAGEMENT LP 12/31/2016 1,447,906 mecosmo2 02/15/17 08:14:44 AM
#26871   39 Institutional Holders eicoman 02/14/17 09:20:31 PM
#26870   anson has 394k shares and 4.9% of the company http://stocknewsflow.com/1017491_0 Chillin up north 02/14/17 09:05:05 PM
#26869   Oke.. this was posted few days ago.. leonardo1 02/14/17 03:58:37 PM
#26868   Must be confusion of share amounts because of PuuliTuku 02/14/17 12:28:32 PM
#26867   Anson Funds Management LP reports a passive stake eicoman 02/14/17 12:06:24 PM
#26866   Anson fund owned 65.86% of APRI as of leonardo1 02/14/17 10:53:34 AM
#26865   not much new today except they seem to eicoman 02/14/17 10:07:20 AM
#26864   Aprivol what he said? Ant other news? carlodb1978 02/14/17 09:34:29 AM
#26863   Room Temp Device coming !!!! Aprilov 02/14/17 09:05:40 AM
#26862   Casinokid see u at 5 usd carlodb1978 02/14/17 05:48:22 AM
#26861   They run out of cash at the end casinokid11211 02/14/17 04:47:05 AM
#26860   Thanks for the explanation. mean gene 02/12/17 11:27:03 PM
#26859   Nasdaq publically traded companies have to meet the OldtimeramI 02/12/17 10:17:46 PM
#26858   Oldtimer, thanks for your post. I am confused mean gene 02/12/17 09:55:30 PM
#26857   Oh Please! OldtimeramI 02/12/17 09:39:42 PM
#26856   Denner is our miracle Be ready tomorrow carlodb1978 02/12/17 05:13:09 PM
#26855   Why give Casino the time of day ??? Aprilov 02/12/17 01:50:32 PM
#26854   A double from here to reach a market mean gene 02/12/17 01:48:33 PM
#26853   A miracle can always be made and I Clariske 02/12/17 11:46:21 AM
#26852   It really doesn't matter who has bought or casinokid11211 02/12/17 10:28:47 AM
#26851   Or is that same filing used when selling PuuliTuku 02/11/17 09:13:15 AM
#26850   Casino you are right that forendo has sold PuuliTuku 02/11/17 09:11:32 AM
#26849   Casino who is the real idiot ? I Aprilov 02/11/17 09:05:03 AM
#26848   I think that 3,000,000 divided by 10 = yorky 02/11/17 08:54:15 AM
#26847   Are you people that retarded, Forendo had 3 casinokid11211 02/11/17 08:17:48 AM
PostSubject